WaveBreak
Xiangyu Teng is a scientist who has experience in the field of drug discovery. Currently working at WaveBreak and University of Cambridge, Xiangyu has a background in biochemistry, biophysics, and molecular biology with degrees from Imperial College London, Minzu University of China, and Peking University. Prior to their current roles, Xiangyu held positions at Imperial College London as a research associate and graduate teaching assistant.
This person is not in any offices
WaveBreak
WaveBreak is a biopharmaceutical company focused on transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.